Penumbra (PEN) R&D In Process (2018)
Penumbra (PEN) reported R&D In Process of $30.8 million for Q3 2018.
Penumbra (PEN) has 1 years of R&D In Process data on file, last reported at $30.8 million in Q3 2018.
- Quarterly R&D In Process changed N/A year-over-year to $30.8 million in Q3 2018, while the trailing twelve-month figure through Dec 2019 was $30.8 million (changed 0.0% YoY) and the FY2018 annual result came in at $30.8 million, changed N/A from the prior year.
- R&D In Process was little changed at $30.8 million in Q3 2018 per PEN's latest filing.
- Across five years, R&D In Process topped out at $30.8 million in Q3 2018 and bottomed at $30.8 million in Q3 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 30.84 Mn |